STOK

In the past six months, Stoke Therapeutics announced presentations of STK-002 at the American Academy of Ophthalmology 2026 Annual Meeting on October 6, 2026, and completed a successful meeting with the FDA to align on the planned U.S. NDA for Zorevunersen on October 5, 2026. On September 23, 2026, Bo Cumbo was appointed to its Board of Directors to enhance commercial expertise. The company released its Q2 2026 earnings report on August 3, 2026, reporting a loss of -$0.93 per share, missing estimates, but revenue of $9.32 million, exceeding estimates. In June 2026, the Phase 3 EMPEROR study for zorevunersen in Dravet syndrome completed enrollment with strong patient retention. Insider trading activity in the past three months saw insiders sell over $1 million in company stock, while Alexander Cumbo was awarded shares. As of October 2026, Stoke Therapeutics holds a "Moderate Buy" consensus rating from 11 Wall Street analysts, with an average price target of $44.25, representing a forecasted upside of 78.86%. The stock experienced a 1-year change of -21.5% and a 1-month change of -20.3% as of October 8, 2026, with its largest daily move being a +15.2% close on October 14, 2025.